Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 17, 2017
Pharmacy Choice - News - Over-the-Counter Drugs - November 17, 2017

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 26     Next >>     Go To Page:

11/17/17 - Improved NSAID Gels with 3x Faster Penetration Rates and 48 Hour Sustained Release Developed by Nemaura Pharma
By a News Reporter-Staff News Editor at Drug Week Sufferers of acute arthritic-related pain using' over the counter' gels to alleviate muscle ache and joint inflammation may be interested in the results of laboratory trials recently carried out by Nemaura Pharma. The UK- based company has developed two new gels which achieve up to three-times fas
11/17/17 - Isodiol International Acquires Global Rights to produce products under an Innovative Delivery System Patent
Isodiol International Inc., a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that it has acquired international licensing rights for IsoDerm? as well as five other proprietary pharmaceutical compounds to be delivered by the patented Direct Effects Technology
11/17/17 - NADDI Releases Third Quarter 2017 Statistics for NPLEx System
By a News Reporter-Staff News Editor at Health& Medicine Week The National Association of Drug Diversion Investigators- the nonprofit organization that facilitates cooperation between law enforcement, healthcare professionals, state regulatory agencies and pharmaceutical manufacturers to prevent and investigate diversion of medicines for...
11/16/17 - Dauphin Clinic Pharmacy - Analyzes the Impact of Technology on Pharmacy Operations
DAUPHIN, MANITOBA, CANADA/ ACCESSWIRE/ November 16, 2017/ The Canadian pharmaceutical industry is the tenth largest in the world. For example, PricewaterhouseCoopers estimates that industry innovation in the United States will generate US $160 billion by 2025, including US $11 billion for data firms alone. Dauphin Clinic Pharmacy recognizes that ne
11/16/17 - Generic Drugs Stock Performance Review Catalyst Pharma, Flexion Therapeutics, Supernus Pharma and Allergan
If you want a Stock Review on CPRX, FLXN, SUPN, or AGN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com shifts focus on Catalyst Pharmaceuticals Inc., Flexion Therapeutics Inc., Supernus Pharmaceuticals Inc., and Allergan PLC. The Generic Drugs market can be segmented into..
11/16/17 - Innovus Pharmaceuticals Strengthens Its Intellectual Property Portfolio with New Patent for Its Sensum+ Product in Mexico
Innovus Pharmaceuticals, Inc., an emerging over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men s and women s health and vitality and respiratory diseases, today announced that i
11/16/17 - Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available
Mitsubishi Tanabe Pharma America, Inc. today announced that more than 1,000 people with amyotrophic lateral sclerosis have been treated with RADICAVA since it became available in the U.S. in August as the first FDA- approved treatment option for the disease in more than 20 years. "After decades of waiting for a treatment option, the ALS commu
11/16/17 - RDD Pharma Raises $9.5M in Series B Funding to Fuel Global Development
NEW YORK and TEL AVIV, Israel, Nov. 16, 2017/ PRNewswire/ RDD Pharma, a leader in developing treatments for lower gastro-intestinal disorders, has raised $9.5 M in Series B funding, including $6 M from two new investors, Pharmascience, Inc. and an international life science fund, as well as existing investors OrbiMed and Capital Point. In paralle
11/16/17 - Sonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn? to Add Antimicrobial Language
Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced that the U.S. Food and Drug Administration has approved an expanded claim for the company s signature dermatology product, Alevicyn?
11/16/17 - Ultragenyx Announces Completion of Patient Dosing in First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has completed patient dosing in the first cohort of three patients enrolled in the Phase 1/ 2 study of DTX301, an adeno-associated virus gene therapy for the treatment of ornithine...
11/15/17 - Acura Pharmaceuticals Announces Third Quarter 2017 Financial Results
PALATINE- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2017. The Company reported a net loss of $2.2 million or $0.12 per diluted share for quarter ended September 30, 2017 compared to a net loss of $2.3 million o
11/15/17 - iReliev Introduces FDA Cleared Therapeutic Wearable Therapy System Approved for Arthritis
The company s line of iReliev brand products offer consumers FDA cleared tools for non-invasive, drug-free pain relief and muscle conditioning. For the nearly 40 million people in the United States that suffer from arthritis, treatment is a constant battle. We ve set out to develop the world s most convenient and easiest to use weara
11/15/17 - Shire plc - CHMP recommends EU Marketing Authorization for Adynovi for adults and adolescents with Hemophilia A
Zug, Switzerland- Shire plc, the world's leading biotechnology company in rare diseases, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the granting of marketing authorization for ADYNOVI, an extended half-life recombinant Factor VIII treatment, for
11/14/17 - ADAMIS PHARMACEUTICALS CORP - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
Information Relating to Forward-Looking Statements. This Quarterly Report on Form 10- Q includes "forward-looking" statements. These forward-looking statements are not historical facts, but are based on current expectations, estimates and projections about our industry, our beliefs and our assumptions.
11/14/17 - Innovus Pharma Enters the $11 Billion Glucose Monitoring Market with FDA-Cleared Products via an Expanded Agreement with ACON Laboratories, Inc. [Syrian Arab News Agency]
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve mens and women`s health and respiratory diseases, today announced that it has entered into an additional agreement with current partner ACON Laboratories,...
11/14/17 - Innovus Pharma Launches FlutiCare? OTC Nasal Spray Allergy Relief in the U.S.
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men s and women's health and respiratory diseases, today announced that it has officially launched FlutiCare? OTC in the U.S. FlutiCare? contains the m
11/14/17 - INNOVUS PHARMACEUTICALS, INC. - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Innovus Pharmaceuticals, Inc., together with its subsidiaries, are collectively referred to as "Innovus", the "Company", "us", "we", or "our". The following information should be read in conjunction with the condensed consolidated financial statements and notes thereto appearing elsewhere in this report. For additional context with which to underst
11/14/17 - INTRICON CORP - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
Headquartered in Arden Hills, Minnesota, IntriCon Corporation is an international company engaged in designing, developing, engineering, manufacturing and distributing body-worn devices. In addition to its operations in Minnesota, the Company has facilities in Illinois, Singapore, Indonesia, Germany and the United Kingdom. The Company sold the card
11/14/17 - KONARED CORP - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Certain information included herein contains forward-looking statements that involve risks and uncertainties within the meaning of Sections 27 A of the Securities Act, as amended; Section 21 E of the Securities Exchange Act of 1934. The factors that might cause such differences include, among others, the following: we have incurred significant loss
11/14/17 - Sun BioPharma Files Form 10-Q for Third Quarter 2017 and Provides Business Update
Sun BioPharma, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today provides a business update and reports financial results for the third quarter ending September 30, 2017. Patient Enrollment Completed in Phase 1 a Trial; As previously announced, the Company completed
11/13/17 - Acura Pharmaceuticals Announces Third Quarter 2017 Financial Results
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2017.. The Company reported a net loss of $2.2 million or $0.12 per diluted share for quarter ended September 30, 2017 compared to a net loss of $2.3 million or $0.19
11/13/17 - ACURA PHARMACEUTICALS, INC - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
This discussion and analysis should be read in conjunction with the Company's financial statements and accompanying notes included elsewhere in this Report. Historical operating results are not necessarily indicative of results in future periods. with Oxford Finance LLC, or to obtain a waiver from Oxford Finance LLC for our.
11/13/17 - CHMP recommends EU marketing authorization for ADYNOVI [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia A
Zug, Switzerland- November 13, 2017- Shire plc, the world's leading biotechnology company in rare diseases, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the granting of marketing authorization for ADYNOVI, an extended half-life recombinant Factor
11/13/17 - Innovus Pharma Enters the $11 Billion Glucose Monitoring Market with FDA-Cleared Products via an Expanded Agreement with ACON Laboratories, Inc.
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men s and women's health and respiratory diseases, today announced that it has entered into an additional agreement with current partner ACON Laboratories,
11/13/17 - Technical Snapshots for These Drug Makers Stocks AstraZeneca, Impax Laboratories, TherapeuticsMD, and GlaxoSmithKline
Ahead of today's trading session, DailyStockTracker.com observes the performance of four major players in this space: AstraZeneca PLC, Impax Laboratories Inc., TherapeuticsMD Inc., and GlaxoSmithKline PLC. Cambridge, the UK headquartered AstraZeneca PLC's stock finished last Friday's session 0.60% lower at $32.91. Additionally, shares of AstraZenec
Articles(s): 1 - 25 of 26     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415